# US 2019/0167858 A1 · Sustained release intraocular implants and methods for treating ocular vasculopathies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0167858 A1
- Document ID: US20190167858A1
- Status: Published application
- Kind: A1
- Application number: 16/272,508
- Filed: 2019-02-11
- Published: 2019-06-06
- Earliest claimed: 2004-04-30
- Assignees: Allergan, Inc.
- Applicants: Allergan, Inc.
- Inventors: Glenn T. Huang; Brittany Jackson; James A. Burke; Ton Lin; Patrick M. Hughes; Larry A. Wheeler; Rosy Sheng Donn
- Web page: https://patentgrep.com/patent/US20190167858A1

## CPC

- A61L 31/148: {Materials at least partially resorbable by the body}
- A61K 9/0051: {Ocular inserts or implants}
- A61K 9/204: {Polyesters, e.g. poly(lactide-co-glycolide)}
- A61K 31/498: Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61L 27/58: Materials at least partially resorbable by the body
- A61L 31/06: obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds {(A61L31/041 takes precedence)}
- A61L 31/16: Biologically active materials, e.g. therapeutic substances {(A61L31/047 takes precedence)}
- A61P 27/02: Ophthalmic agents
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 27/16: Otologicals
- A61P 31/04: Antibacterial agents
- A61P 31/12: Antivirals
- A61P 31/18: for HIV
- A61P 33/00: Antiparasitic agents
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C08L 67/04: Polyesters derived from hydroxycarboxylic acids, e.g. lactones (C08L67/06 takes precedence)
- A61L 2300/436: of receptors
- A61L 2300/604: Biodegradation
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C08L: COMPOSITIONS OF MACROMOLECULAR COMPOUNDS (compositions based on polymerisable monomers C08F, C08G; artificial filaments or fibres D01F; textile treating compositions D06)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat one or more ocular conditions, such as an ocular vasculopathy or glaucoma, among others.

## Claims

### Claim at position 1

-42. (canceled)

### Claim 43

A method of treating non-exudative age related macular degeneration in an eye of a patient, comprising the step of placing a solid extruded biodegradable intraocular implant in an eye of the patient to provide a therapeutically effective amount of an alpha-2 adrenergic receptor agonist to the patient for at least about one week, wherein the implant comprises the alpha-2 adrenergic receptor agonist associated with a biodegradable polymer matrix that releases alpha-2 adrenergic receptor agonist at a rate effective to sustain release of an amount of the alpha-2 adrenergic receptor agonist from the implant for a time effective to treat non-exudative age related macular degeneration in the eye in which the implant is placed, and wherein the polymer matrix comprises two different polylactide polymers.

### Claim 44 (depends on 43)

The method of claim 43, wherein the alpha-2 adrenergic receptor agonist is selected from the group consisting of brimonidine tartrate and brimonidine free base.

### Claim 45 (depends on 44)

The method of claim 44, wherein the implant is placed in the vitreous cavity of the eye.

### Claim 46 (depends on 43)

The method of claim 43, wherein the implant is placed in the eye with a trocar.

### Claim 47 (depends on 45)

The method of claim 45, wherein the implant is injected into the eye with a syringe.
